血浆Aβ(淀粉样蛋白β)水平与小血管病的严重程度及进展
基于RUN DMC队列487名参与者(其中258人完成9年内3次MRI评估),采用ELISA测定基线血浆Aβ38、Aβ40、Aβ42水平,经协方差分析校正年龄、性别和高血压后发现,血浆Aβ水平与小血管病影像标志物的存在及进展相关,提示Aβ病理可能参与小血管病的发生发展。
要点
- 横断面分析中,有微出血者血浆Aβ40水平升高(均值205.4 vs 186.4 pg/mL,P<0.01)。
- 横断面分析中,有腔隙灶者血浆Aβ40水平升高(均值194.8 vs 181.2 pg/mL,P<0.05)。
- 纵向分析中,白质高信号进展者血浆Aβ40水平升高(均值194.6 vs 182.9 pg/mL,P<0.05)。
核心结论
- 血浆Aβ水平与小血管病标志物的存在及进展均相关,提示Aβ病理可能参与小血管病的发生与进展。
- 血浆Aβ水平可能作为廉价、无创的指标,用于识别小血管病进展风险较高的个体。
研究设计与样本
- 研究纳入RUN DMC研究(Radboud大学Nijmegen弥散张量及磁共振成像队列)的487名参与者,其中258人在9年内完成3次MRI评估。
- 采用ELISA测定基线血浆Aβ38、Aβ40和Aβ42水平,半自动评估白质高信号体积,手动评级腔隙灶和微出血。
- 采用协方差分析校正年龄、性别和高血压,分析血浆Aβ与小血管病标志物的关联。
主要发现
- 横断面分析:有微出血者血浆Aβ40均值205.4 vs 186.4 pg/mL(P<0.01);有腔隙灶者Aβ40均值194.8 vs 181.2 pg/mL(P<0.05)。
- 横断面分析:严重白质高信号者Aβ38均值25.3 vs 22.7 pg/mL(P<0.01),Aβ40均值201.8 vs 183.3 pg/mL(P<0.05)。
- 纵向分析:白质高信号进展者血浆Aβ40均值194.6 vs 182.9 pg/mL(P<0.05)。
- 纵向分析:新发腔隙灶者Aβ38均值24.5 vs 22.5 pg/mL(P<0.05),Aβ40均值194.9 vs 181.2 pg/mL(P<0.01)。
- 纵向分析:新发微出血者Aβ42均值62.8 vs 60.4 pg/mL(P<0.05)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: Cerebral small vessel disease (SVD) is a frequent pathology in aging and contributor to the development of dementia. Plasma Aβ (amyloid β) levels may be useful as early biomarker, but the role of plasma Aβ in SVD remains to be elucidated. We investigated the association of plasma Aβ levels with severity and progression of SVD markers. METHODS: We studied 487 participants from the RUN DMC study (Radboud University Nijmegen Diffusion Tensor and Magnetic Resonance Imaging Cohort) of whom 258 participants underwent 3 MRI assessments during 9 years. We determined baseline plasma Aβ38, Aβ40, and Aβ42 levels using ELISAs. We longitudinally assessed volume of white matter hyperintensities semiautomatically and manually rated lacunes and microbleeds. We analyzed associations between plasma Aβ and SVD markers by ANCOVA adjusted for age, sex, and hypertension. RESULTS: Cross-sectionally, plasma Aβ40 levels were elevated in participants with microbleeds (mean, 205.4 versus 186.4 pg/mL; P<0.01) and lacunes (mean, 194.8 versus 181.2 pg/mL; P<0.05). Both Aβ38 and Aβ40 were elevated in participants with severe white matter hyperintensities (Aβ38, 25.3 versus 22.7 pg/mL; P<0.01; Aβ40, 201.8 versus 183.3 pg/mL; P<0.05). Longitudinally, plasma Aβ40 levels were elevated in participants with white matter hyperintensity progression (mean, 194.6 versus 182.9 pg/mL; P<0.05). Both Aβ38 and Aβ40 were elevated in participants with incident lacunes (Aβ38, 24.5 versus 22.5 pg/mL; P<0.05; Aβ40, 194.9 versus 181.2 pg/mL; P<0.01) and Aβ42 in participants with incident microbleeds (62.8 versus 60.4 pg/mL; P<0.05). CONCLUSIONS: Plasma Aβ levels are associated with both presence and progression of SVD markers, suggesting that Aβ pathology might contribute to the development and progression of SVD. Plasma Aβ levels might thereby serve as inexpensive and noninvasive measure for identifying individuals with increased risk for progression of SVD.
引用
- van Leijsen EMC, Kuiperij HB, Kersten I, et al. Plasma Aβ (Amyloid-β) Levels and Severity and Progression of Small Vessel Disease. Stroke. 2018. PMID: 29540613. doi:10.1161/STROKEAHA.117.019810
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。